Synopsis The optimal concentration of Atropine in myopia treatment is uncertain. The present study aimed to evaluate the safety and efficacy of low concentration atropine eye drops at 0.05%, 0.025%, and 0.01% and compared with placebo for a period of 1 year. This week’s “MED FACT” discusses a clinical trial from Ophthalmology, “Low-Concentration Atropine for Myopia Progression (LAMP) Study”. Authors: Yam, Jason C., et al.
Key Takeaways 0.05% atropine was most effective in controlling SE progression and AL elongation Objective: To evaluate the safety and efficacy of low concentration atropine eye drops Study Type: A Randomized, Double-Blinded, Placebo-Controlled Trial Participants: 438 What Was The Need For This Study? Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy and optimal concentration remain uncertain. Thus, this study was thought to…
